Bayer shifts US glyphosate business to Ruveon after seeking tariffs on Chinese imports
Bayer shifts US glyphosate business to Ruveon after seeking tariffs on Chinese imports July 1 (Reuters) - Bayer BAYGn.DE said on Wednesday it is consolidating its U.S. glyphosate business into its Ruveon unit, a day after it asked Washington to impose duties on Chinese imports of the chemical used in the company's weedkiller Roundup.
Bayer, the only U.S. maker of glyphosate, sought duties against Chinese imports of the chemical and said on Tuesday that "the domestic glyphosate business as it stands today is not sustainable", angering farmers who said such a move would raise herbicide costs.
The St. Louis-based unit, which remains a Bayer business, will oversee all aspects of U.S. glyphosate sales, including pricing, go-to-market strategies, production and logistics, the company said on Wednesday.
Bayer said the consolidation of the business was part of its Crop Science division's five-year restructuring plan.
"Ruveon is expected to be a more nimble and well-positioned player within its commodity-based market, which requires a specialized approach to address competitive dynamics," Bayer said.
Last week, the German pharmaceuticals and agriculture group scored a major legal victory when the U.S. Supreme Court blocked thousands of state-court lawsuits that accuse Bayer of failing to warn users that glyphosate causes cancer.
Ruveon will be led by Bayer veteran Alfonso Alba Ordonez.
(Reporting by Bipasha Dey in Bengaluru; Editing by Sherry Jacob-Phillips)
((Bipasha.Dey@thomsonreuters.com;))
Recent news on Bayer AG
See all newsBrief: Bayer Says Finerenone Slowed Kidney Decline In CKD
Insight: How cheap Chinese antibiotics threaten Europe's last major penicillin plant
Deutsche Bank AG FF - Post Stabilisation Notice -Bayer EUR 30NC6 & 30NC9
Brief: Bayer To Present New Finerenone Data Across Chronic Kidney Disease With And Without Diabetes At Asn Kidney Week 2026
Brief: FDA Approves Once-Weekly Generic Hormone Therapy Patch For Women